A nonprofit U.S. organization that was formed in August of 1 994 by a group of research institutions and companies. The Consortium’s first president is Stuart A. Kauffman of the Santa Fe Institute. The Consortium’s purpose is to further the use of molecular diversity as a tool in drug design and in the study of mutating viruses.